CytoSorbents Corporation (CTSO)

[cars100cars]

Pears, actually I agree with you, cost notwithstanding. The greatest failing of CTSO to date is failure to achieve approval in the US. The cardiac surgery pathway certainly is the most promising avenue, likely with far lower cost for trials and less risk than sepsis. I was against the sepsis pathway and spending 25 million on it. But for cardiac surgery, I'm 100% in favor of CTSO spending anything to obtain FDA approval for this indication. The sepsis pathway was fraught with problems, particularly since the diverse reasons and age groups that contract sepsis. The cardiac surgery patients are much more defined and thus measurable and analyzed. If I were CEO, nothing would stand in the way of moving the next steps forward on cardiac surgery. Once CytoSorb is in hospitals, docs would begin using it off-label for sepsis and other indications.